Look, we have a science problem, but it’s not the one you think. For decades, the conversation around women’s health has been stuck in the laboratory, focused almost exclusively on the "missing science": the clinical trials that excluded women and the drugs that were never tested on female biology. That research gap is real, and it’s massive. But a landmark report released this month by the World Economic Forum and the McKinsey Health Institute, titled CARE for Women: Investing in Care Delivery to Improve Women's Lives and Livelihoods, just shifted the goalposts.
Here’s the thing: while we wait for the next ten years of biotech to catch up, there is a $1 trillion opportunity sitting right in front of us that doesn't require a single new molecule or a breakthrough patent.
Women spend about 25% more of their lives in poor health than men. It’s a staggering disparity that drains productivity, hollows out families, and stunts global GDP. The central finding of the May 2026 report is that roughly a third of this health gap: 34% to be exact: comes not from weak therapies or missing science, but from how care is actually delivered. We’re talking about missed screenings, delayed diagnoses, and fragmented follow-up.
This is an execution problem. And at McFadden Finch Holdings Company, we know that execution problems are where visionary capital and operational excellence meet to create the most impact.
The Invisible 34%: Why the System is Failing by Default
Most of the time, when a woman’s health issue goes unresolved, it’s because she fell through a crack that was built into the system. The science exists. The diagnostics exist. But the pathways connecting them? They’re broken.
The report breaks the women’s health gap into three buckets: efficacy (58%), lack of data (8%), and care delivery (34%). While efficacy and data require long-term, high-risk R&D, that 34% represents the most fixable piece of the puzzle. It’s the "low-hanging fruit" of global health equity, provided you have the scale and the strategy to reach it.
Honestly, it’s a bit of a wake-up call for health system leaders and private investors alike. We’ve been searching for complex answers when a huge part of the solution is simply moving from knowing what to do to consistently doing it at scale.
The CARE Framework: A Blueprint for Action
To tackle this, the report introduces the CARE framework. It’s a strategic tool designed to help stakeholders: from governments to private equity firms like our own Nucleus Holdings: identify exactly where the friction is.
- C: Conduct research and gather clinical evidence. This isn't just about the lab; it’s about real-world data. We need to know how social determinants and care delivery models affect outcomes in real-time.
- A: Align care and integrate referral pathways. This is the "infrastructure" of health. It means making sure that a finding in one clinic (like a mammogram) triggers the right action in another (like a cardiology consult) without the patient having to play project manager for her own life.
- R: Report using clear guidelines and standards. If it isn't measured, it isn't managed. We need standardized reporting that flags women-specific risks as a default, not an afterthought.
- E: Engage patients and health system stakeholders. This is about patient-centered care. It’s about ensuring women have the agency and the information to advocate for themselves within a system that often overlooks them.
The Heart in the Mammogram: The BAC Opportunity
One of the most compelling examples in the report is Breast Arterial Calcification (BAC).
Most women over 40 get regular mammograms. It’s a standard, high-volume screening. What most people don’t realize: including many doctors: is that those mammograms often show calcium buildup in the breast artery walls. This is BAC. It has nothing to do with cancer, but it is a massive red flag for cardiovascular disease.
Women with BAC face a 58% higher risk of cardiovascular events and are 1.5 times more likely to experience heart failure. The crazy part? This data is already sitting in the images. But because the radiologist is looking for cancer, and there is no standard referral pathway to a cardiologist, that information usually stays buried in the file.
The ideal state is simple: radiologists flag the BAC and automatically route the results to a primary care physician or cardiologist for a heart-risk assessment. The cost? About $500 per woman for preventive care. The alternative? A $120,000 cardiovascular event down the road. This is the kind of math that should make every payer and investor lean in.
Pregnancy as a Lifetime Stress Test
We often treat pregnancy as a self-contained nine-month event. But the WEF report argues we should see it as a "stress test" for a woman’s long-term health.
Conditions like pre-eclampsia and gestational diabetes aren't just temporary complications; they are powerful predictors of cardiovascular and metabolic disease later in life. Yet, once the baby is born, the monitoring usually stops. The patient is often left to track her own recovery while navigating the exhaustion of new motherhood.
In the U.S. alone, closing the care delivery gap in pregnancy-related cardiovascular risk could avert tens of thousands of strokes and heart attacks. It requires moving from fragmented, episodic care to a longitudinal model that follows a woman long after she leaves the delivery room.
Perinatal Depression: The Hidden Economic Drain
The report also dives deep into perinatal depression, which affects about 20% of women during or after pregnancy. It is one of the most underdiagnosed conditions in the world, largely due to stigma and inconsistent screening.
In the UK, suicide is the leading cause of maternal death between six weeks and one year post-partum. That is a devastating statistic that points directly to a failure in care delivery.
Beyond the human cost, the economic toll is massive. Untreated maternal mental health issues cost an estimated $14.2 billion in lost economic opportunity each year in the U.S. alone. But the ROI on treatment is stellar: between 3x and 6x. By integrating routine screening with validated tools like the PHQ-9 into standard obstetric care, we can reclaim roughly 60 to 110 healthy days for every woman treated.
The ROI of Equity: Why This is a Business Mandate
At MFHC, we often talk about "Philanthropreneurship": the idea that business growth should serve community impact. The WEF/McKinsey report proves that in women’s health, the two are inseparable.
Closing the women’s health gap could add at least $1 trillion to the global economy by 2040. But let’s look at the immediate, operator-level returns:
- Preventive care delivers a 3x to 6x ROI. By shifting spending from high-cost acute events (like heart failure) to low-cost prevention (like $500 screenings), health systems save millions.
- BAC scaling could avert 60,000 events. Over seven years, a systematic approach to BAC could save the U.S. healthcare system billions in avoided costs.
- Workforce Participation. When women are healthy, they stay in the workforce. In a region like the Bay Area, where talent is our most valuable currency, keeping women healthy is a competitive necessity.
We aren't just talking about doing the right thing. We're talking about the most logical, high-impact investment strategy available in the professional services and healthcare sectors today.
Solutions Across Scales: From Baseline to Advanced
The beauty of the CARE report is that it doesn't offer a one-size-fits-all solution. It recognizes that a clinic in Oakland has different resources than a public health program in Nepal. The solutions are tiered:
- Baseline (Level 1): Standardizing where BAC is noted on a radiology report or implementing a basic "how are you feeling?" depression screen.
- Intermediate (Level 2): Using digital maternal health "passports" to track pregnancy complications across different providers.
- Advanced (Level 3): Deploying AI-assisted BAC detection and building perinatal mental health centers of excellence that use a two-generation care model.
Whether you are a local clinic or a global health tech firm, there is a level of intervention that fits your capacity.
A Call to Action for Stakeholders
Closing a 34% gap in care delivery requires a coordinated effort. No single actor can do this alone.
- Payers: It’s time to reimburse for longitudinal care. In 2025, BAC reporting finally became a CMS-approved quality measure. This is the kind of policy shift that changes behavior overnight.
- Governments: We need updated guidelines and a workforce trained in women-specific risk factors.
- Private Sector: From biopharma to medtech, we need the AI tools and diagnostics that make the CARE framework easy to implement.
- Patients: Self-advocacy is vital. We need to empower women with the data to ask: "Was there BAC on my mammogram?" or "How does my pre-eclampsia history affect my heart health today?"
Building the Future of Care
At McFadden Finch Holdings Company, our portfolio is built on the belief that infrastructure: whether it’s a real estate development or a healthcare delivery system: must be designed for the people it serves.
The "Care Delivery Revolution" is about more than just medicine. It’s about building lasting institutions that recognize the unique needs of women and provide the connected, high-quality care they deserve. By bridging the gap between visionary capital and community-centric development, we aren't just improving health; we’re driving sustainable growth and transformation across the Bay Area and beyond.
The tools are here. The math is clear. Now, it’s just a matter of execution.
Built to grow strong businesses, meaningful partnerships, and lasting community impact. Connect with McFadden Finch Holdings Company today.
McFadden Finch Holdings Company
Vision. Leadership. Lasting Impact.
Lake Merritt Plaza
1999 Harrison Street, Suite 1872-73
Oakland, CA 94612
(510) 973-2677
www.m-fhc.com
info@m-fhc.com
McFadden Finch Holdings Company (MFHC) is a premier holdings and investment management firm dedicated to driving sustainable growth and long-term value. Our mission is to bridge the gap between visionary capital and community-centric development, ensuring tomorrow’s infrastructure meets today’s needs. Through strategic project management and rigorous market analysis, we empower our partners to navigate the complexities of the California economic landscape with confidence and clarity.
For more information on how MFHC can support your industrial or real estate investment strategy, contact us at (510) 973-2677 or visit www.m-fhc.com.
Based on the story by World Economic Forum + McKinsey Health Institute | Insight Report, May 2026.
Sources
- World Economic Forum. (2026). CARE for Women: Investing in Care Delivery to Improve Women's Lives and Livelihoods.
- McKinsey Health Institute. (2026). The $1 Trillion Opportunity in Women’s Health.
- World Economic Forum. (2026). The Care Framework: A Blueprint for Health Equity.
- Centers for Medicare & Medicaid Services (CMS). (2025). MIPS Quality Measures for Radiology.
- PANDAS Foundation UK. (2026). Perinatal Mental Health Advocacy and Support.
Disclaimer: This content is for general informational purposes only and does not constitute legal, financial, tax, investment, real estate, business, or other professional advice. Reading this content does not create an advisory, client, fiduciary, or contractual relationship with McFadden Finch Holdings Company. Because every business, investment, property, and strategic situation is different, you should consult qualified professionals regarding your specific circumstances. McFadden Finch Holdings Company makes no warranties regarding the accuracy or completeness of this information and is not responsible for third-party content, links, products, services, or organizations referenced. Testimonials, examples, case studies, and projected outcomes are illustrative only and do not guarantee similar results.
